sorafenib has been researched along with vincristine in 3 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (vincristine) | Trials (vincristine) | Recent Studies (post-2010) (vincristine) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 246 | 0 | 117 |
| Protein | Taxonomy | sorafenib (IC50) | vincristine (IC50) |
|---|---|---|---|
| Tubulin beta-4A chain | Homo sapiens (human) | 0.5 | |
| Tubulin beta chain | Homo sapiens (human) | 0.5 | |
| Tubulin alpha-3C chain | Homo sapiens (human) | 0.5 | |
| Tubulin alpha-1B chain | Homo sapiens (human) | 0.5 | |
| Tubulin alpha-4A chain | Homo sapiens (human) | 0.5 | |
| Tubulin beta-4B chain | Homo sapiens (human) | 0.5 | |
| Tubulin beta-3 chain | Homo sapiens (human) | 0.5 | |
| Tubulin beta-2A chain | Homo sapiens (human) | 0.5 | |
| Beta-tubulin | Leishmania donovani | 1 | |
| Tubulin beta-8 chain | Homo sapiens (human) | 0.5 | |
| Tubulin beta-2B chain | Bos taurus (cattle) | 1.8 | |
| Tubulin alpha-3E chain | Homo sapiens (human) | 0.5 | |
| Tubulin alpha-1A chain | Homo sapiens (human) | 0.5 | |
| Similar to alpha-tubulin isoform 1 | Bos taurus (cattle) | 1.8 | |
| Similar to alpha-tubulin isoform 1 | Bos taurus (cattle) | 1.8 | |
| Tubulin alpha-1C chain | Homo sapiens (human) | 0.5 | |
| Tubulin beta-6 chain | Homo sapiens (human) | 0.5 | |
| Tubulin beta-2B chain | Homo sapiens (human) | 0.5 | |
| Tubulin beta-1 chain | Homo sapiens (human) | 0.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Abdelatef, SA; Abdelazeem, AH; Abdellatif, KRA; Amin, NH; El-Saadi, MT; Omar, HA | 1 |
| Xu, Z; Zhang, L | 1 |
2 review(s) available for sorafenib and vincristine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Coumarin-containing hybrids and their anticancer activities.
Topics: Animals; Antineoplastic Agents; Coumarins; Drug Design; Drug Discovery; Humans; Neoplasms; Structure-Activity Relationship | 2019 |
1 other study(ies) available for sorafenib and vincristine
| Article | Year |
|---|---|
Design, synthesis and anticancer evaluation of novel spirobenzo[h]chromene and spirochromane derivatives with dual EGFR and B-RAF inhibitory activities.
Topics: Antineoplastic Agents; Benzopyrans; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Molecular Structure; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Spiro Compounds; Structure-Activity Relationship | 2018 |